睿智医药(300149) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥283,050,158.28, representing an increase of 11.72% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥18,290,817.17, a significant decrease of 1,575.68% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥21,141,831.69, down 322.61% from the previous year[5]. - The company reported a net cash flow from operating activities of ¥120,235,170.12, an increase of 6.83% year-to-date[5]. - The company implemented an equity incentive plan, which impacted the net profit figures, showing a net profit of ¥42,728,200 for the first three quarters of 2025, a year-on-year increase of 169.29%[5]. - The net profit attributable to shareholders of the listed company for the first three quarters of 2025 was CNY 42.73 million, representing a year-on-year increase of 169.29%[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 21.29 million, showing a year-on-year growth of 130.83%[19]. - Net profit for the current period was ¥7,162,056.65, a significant recovery from a net loss of ¥61,782,349.49 in the previous period[25]. - The company reported a total comprehensive income of ¥4,882,472.92, compared to a loss of ¥71,216,290.10 in the prior period[26]. - Basic and diluted earnings per share improved to ¥0.0142 from a loss of ¥0.1238 in the previous period[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,989,453,565.68, a decrease of 0.32% compared to the end of the previous year[5]. - The total current assets as of September 30, 2025, amounted to CNY 697.46 million, an increase from CNY 644.07 million at the beginning of the period[20]. - The total assets of the company were CNY 1.99 billion, slightly down from CNY 1.996 billion at the beginning of the period[21]. - The total liabilities of the company as of September 30, 2025, were CNY 332.73 million, compared to CNY 346.70 million at the beginning of the period[21]. - The total liabilities decreased to ¥711,624,278.12 from ¥757,745,151.71, indicating a reduction of approximately 6.1%[22]. - Total equity attributable to shareholders of the parent company increased to ¥1,253,557,011.18 from ¥1,213,861,296.55, reflecting a growth of 3.3%[22]. - Deferred income decreased to ¥24,889,143.90 from ¥28,360,653.06, a decline of 12.3%[22]. Cash Flow - Cash flow from operating activities generated ¥120,235,170.12, an increase from ¥112,545,118.85 in the previous period[27]. - The net cash flow from investment activities was -$54.49 million, a decrease from -$58.43 million in the previous period[28]. - Total cash inflow from financing activities was $40.30 million, compared to $28.45 million in the prior period[28]. - The net cash flow from financing activities was -$65.05 million, an improvement from -$81.21 million year-over-year[28]. - The ending balance of cash and cash equivalents was $362.39 million, down from $313.53 million in the previous year[28]. - The company reported a total cash outflow from investment activities of $133.89 million, significantly higher than $64.23 million last year[28]. - Cash received from borrowings amounted to $5.00 million, a decrease from $28.45 million in the previous period[28]. - The cash outflow for repayment of debts was $14.26 million, compared to $62.13 million in the previous year[28]. Expenses - The company’s sales expenses increased by 50.37% to ¥42,602,703.70 due to higher marketing and advertising costs[11]. - The investment income rose by 89.47% to ¥13,835,351.40, primarily from the sale of equity in a subsidiary[11]. - The company recognized share-based payment expenses of CNY 35.64 million for the equity incentive plan during the first three quarters of 2025[19]. - The company reported an increase in research and development expenses to ¥41,853,143.70 from ¥45,275,069.93, a decrease of 7.5%[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 42,558[12]. - The company granted 44.56 million restricted stock to 123 incentive objects at a grant price of CNY 3.05 per share on July 11, 2025[18]. - The company plans to implement a stock incentive plan as approved in the shareholder meeting held on May 30, 2025[18]. Miscellaneous - The company's long-term equity investments decreased from CNY 214.46 million to CNY 166.12 million during the reporting period[21]. - The company’s third-quarter financial report was not audited[29].